Introduction

Lentivirus is one of the widely used viral vectors in cell & gene therapy. Our client, a leading CAR-T therapeutic company in China, utilizes lentiviral vectors to deliver specific T-cell receptor genes into patient-derived T cells. However, the conventional four-plasmid transfection production process is inherently expensive, with lentiviral vectors contributing significantly to the overall cost of their current TCR-T cell therapy pipelines.

Seeking a more cost-effective solution for large-scale lentiviral vector production, our client adopted the EuLV™ stable producer cell line system to produce lentiviral vectors. The data below demonstrates how this system has enabled our client to reduce the lentiviral vector production cost.

EurekaBio Solution

What’s the EuLV™ Stable Producer Cell Line System

The EuLV™ stable producer cell line system provides a plasmid-free method for LVV production. It integrates the GOI into the HEK293T packaging cell line genome and utilizes double molecular switchers for precise control over gene expression. Additionally, the producer cells are adapted to suspension culture, allowing for high-density culture in a chemically defined medium. This system eliminates the need for total plasmid manufacture and transfection steps, resulting in higher titers and improved process robustness.

In this case study, we will use real-world customer case data to illustrate the development of the stable producer cell line and how this system reduces the cost of LVV production.